US Pharmacopeia: Industry and policymakers agree—drug shortages are not over
US Pharmacopeia shared a post on LinkedIn:
“To adequately solve drug shortages, we need to look more broadly at the resiliency of the medicine supply chain to [better] understand vulnerabilities and risks.’
Vimala Raghavendran | US Pharmacopeia VP Informatics Product Development
Industry and policymakers agree—drug shortages are not over. Active drug shortages remain at the highest level since 2014, while over half of the drugs that are in shortage have been in limited availability for at least two years.
Last week, congressional leaders convened a hearing on our nation’s ongoing drug shortage crisis. American Society of Clinical Oncology (ASCO) Chief Medical Officer Dr. Julie Gralow spoke on behalf of cancer practitioners and patients, who she described as ‘facing some of the worst oncology drug shortages to date.’ Echoing fellow witnesses, Dr. Gralow’s testimony called for urgent solutions, emphasizing that persistent shortages force healthcare providers to make impossible choices, leaving patients to face the repercussions.
Join us and protect access to quality, critical medicines through a more resilient supply chain. Check out our policy recommendations and re-post to spread the word for a national call to action. For more, read our full statement submitted to the U.S. House Committee on Ways and Means”
Source: US Pharmacopeia/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023